TWD
TLX

True Wealth Design’s Telix Pharmaceuticals TLX Stock Holding History

True Wealth Design’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$23 – 2833
2025
Q4 		$23 Hold
3
– – ﹤0.01% 2477
2025
Q3 		$29 Sell
3
-7
-70% -$86 ﹤0.01% 2636
2025
Q2 		$161 Buy
+10
New +$168 ﹤0.01% 2127

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $6.97B AUM 29.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

True Wealth Design's TLX Position: Q1 2026 in Review

True Wealth Design sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 3 shares — an estimated $23 sold.

True Wealth Design first reported a position in TLX in Q2 2025 and held it in 3 quarters. The position peaked at $161 in Q2 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • True Wealth Design reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • True Wealth Design sold 3 Telix Pharmaceuticals shares in Q1 2026, an estimated $23.
  • True Wealth Design first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • True Wealth Design's Telix Pharmaceuticals position peaked at $161 in Q2 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on True Wealth Design's 13F filing for Q1 2026, filed 13 Apr 2026.